Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





PENTABORANE								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 19624-22-7; **Chemical Formula:** B5H9
OSHA’s former limit for pentaborane was 0.005 ppm as an 8-hour TWA. The ACGIH has the same 8-hour TWA but additionally recommends a 15-minute STEL of 0.015 ppm. The Agency proposed, and the final rule establishes, permissible exposure limits of 0.005 ppm as an 8-hour TWA and 0.015 ppm as a 15-minute STEL for pentaborane. NIOSH (Ex. 8-47, Table N1) concurs that these limits are appropriate. Pentaborane is a colorless liquid with a strong and penetrating odor.
In both humans and animals, inhalation of pentaborane vapor causes central nervous system effects (Svirbely 1954a/ Ex. 1-385; Rozendaal 1951/Ex. 1-525; Lowe and Freeman 1957/ Ex. 1-518; Cordasco, Cooper, Murphy, and Anderson 1962/ Ex. 1-545).
The 5-minute LC(50) for rats and mice is 67 and 40 ppm, respectively; for 60 minutes, these values are 10 and 6 ppm for rats and mice, respectively (Weir, Bath, and Weeks 1961, as cited in ACGIH 1986/Ex. 1-3, p. 459). Rats exposed repeatedly to 3 ppm pentaborane by inhalation exhibited tremors, hyper-excitability, belligerence, and weight loss (Svirbely 1954a/ Ex. 1-385). Rats, rabbits, monkeys, and dogs exposed repeatedly to pentaborane vapor at concentrations of 1 ppm for four weeks or 0.2 ppm for six months lost weight (Levinskas, Paslian, and Bleckman 1958/Ex. 1-517). In the same experiments, rats and rabbits exposed at 1 ppm showed reduced activity and impaired locomotor ability, respectively, and monkeys and dogs exhibited apathy, loss of appetite, insensitivity to pain, loss of mobility, tremor, and impaired coordination. The ACGIH (1986/Ex. 1-3, p. 459) notes that the 0.2-ppm concentration reported in the Levinskas, Paslian, and Bleckman (1958/Ex. 1-517) study was a calculated rather than measured value and that the actual exposure level was probably closer to 0.01 ppm.
Humans accidentally overexposed to pentaborane experienced tremors, convulsions, behavioral changes, loss of memory, impaired judgment, and other symptoms of central nervous system intoxication (Svirbely 1954a/Ex. 1-385; Rozendaal 1951/ Ex. 1-525; Lowe and Freeman 1957/Ex. 1-518; Cordasco, Cooper, Murphy, and Anderson 1962/Ex. 1-545). No comments other than those from NIOSH were received on the health effects associated with pentaborane exposure.
OSHA is establishing an 8-hour TWA PEL of 0.005 ppm and a 15-minute STEL of 0.015 ppm for pentaborane. The Agency concludes that these limits will protect workers against the significant risk of central nervous system effects, such as tremors and convulsions, behavioral changes, and loss of judgment, potentially associated with exposure to pentaborane at levels only slightly above those formerly permitted by the 8-hour TWA alone. OSHA finds that these neuropathic effects constitute material health impairments within the meaning of the Act.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue